Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 14/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23389149 | 1.00 | BTK (0.37) | BTKROCK2DDR1S1PR2KDM4E | |
| SCHEMBL23389186 | 0.86 | ROCK2 (0.45) | BTKROCK2DDR1KDM4EALDH1A1 | |
| SCHEMBL23389189 | 0.86 | ROCK2 (0.45) | BTKROCK2DDR1KDM4EALDH1A1 | |
| SCHEMBL25987671 | 0.86 | BTK (0.38) | BTKROCK2DDR1PDE2A | |
| SCHEMBL23419041 | 0.86 | ROCK2 (0.37) | ROCK2DDR1S1PR2KDM4EALDH1A1 | |
| SCHEMBL25987724 | 0.81 | HRH4 (0.40) | BTK | |
| SCHEMBL23419001 | 0.80 | ALDH1A1 (0.36) | ROCK2S1PR2KDM4EALDH1A1HPGD | |
| SCHEMBL23419006 | 0.77 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDHSD17B10GRIN1 | |
| SCHEMBL23389097 | 0.76 | ROCK2 (0.44) | BTKROCK2DDR1KDM4E | |
| SCHEMBL23389100 | 0.76 | ROCK2 (0.44) | BTKROCK2DDR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263366-A2 | CASPASE 6 INHIBITORS AND USES THEREOF | SHANGPHARMA INNOVATION INC. | 2025-08-21 | — | — | US | disclosed |
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
| CN-115335039-A | Caspase 6 inhibitors and uses thereof | 加利福尼亚大学董事会 | 2022-11-11 | — | — | CN | disclosed |
| EP-4061341-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | The Regents of the University of California (US) | 2022-09-28 | — | — | EP | disclosed |
| WO-2021102361-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021102361-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | CASP6, CASP1, CASP10 | BTK 3023/4885ROCK2 3549/4885DDR1 1956/4885 |
| US-20250263366-A2 | CASPASE 6 INHIBITORS AND USES THEREOF | CASP6, CASP1, CASP10 | BTK 3023/4885ROCK2 3549/4885DDR1 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.